Liege, Belgium, 29 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 6, April 2022.

Goldman Sachs has notified Mithra on 27, April 2022 that it has exceeded the statutory 3% threshold on 22, April 2022 and then has crossed downwards the statutory 3% threshold on 25, April 2022.

Liege, Belgium, 26 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA) today announces a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège.

Mithra CDMO offers a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges.

Liege, Belgium, 20 April 2022 – 07:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that Goldman Sachs International (“GSI”) has elected to exercise a call option for an amount of EUR 5,000,000 on 19 April, 2022, according to the terms of the equity funding agreement signed with GSI on February 4, 2022. This call option will result in the issuance of 489,686 shares of the Company.

Liege, Belgium, 19 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the invitation to its ordinary and extraordinary securities holders’ meeting that will be held on Thursday May 19 2022 at 2:00 PM (CEST).

The notice for the General Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Liege, Belgium, 18 April 2022 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (“Mithra” or the “Company”), a company dedicated to Women’s Health, today announces the extension of the capital commitment agreement with LDA Capital Limited (“LDA Capital“) for a period of two additional years, as well as the increase of the commitment amount by EUR 25 million.

Liege, Belgium, 15 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2021 Annual Report. The Annual Report which outlines Mithra’s achievements in 2021 includes the following information:

– Overview of Mithra’s R&D pipeline and letter to shareholders;
– Highlights of Mithra’s strategy and outlook for 2022;
– Brand new section dedicated to Mithra’s ESG strategy;
– Management report;
– Remuneration report;
– Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website report2021.mithra.com or on investors.mithra.com.

• Consolidated analysis of Phase 3 topline data showed even more positive results than initially announced, with all four co-primary endpoints met
• Donesta® safety profile confirmed by independent Data Safety Monitoring Board (DSMB), which recommended to continue the Phase III Clinical Program
• Launch of the recruitment of the additional 300 menopausal women thanks to a successful mitigation plan

Liege, Belgium, 14 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces consolidated positive topline results of Phase 3 Donesta® Program. Donesta® is Mithra’s next generation orally-administrated estetrol (E4)-based hormone therapy product candidate offering a potential long-term solution for treating different symptoms of menopause,  simultaneously or sequentially, caused by estrogen loss.

Liege, Belgium, 8 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 6, April 2022. Goldman Sachs has notified Mithra that it has dropped below the legal 3% threshold on 1, April 2022.